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Relationship Between Pulmonary Airflow (FEV1) and Use of Menthol vs Non-Menthol 
Cigarettes in the COPDGene® Population 
 
Jodi Ann Kanyuch, MPH 
 







Chronic Obstructive Pulmonary disease (COPD) is the fourth leading causes of death in 
the United States and a major public health issue.  The relationship between smoking and COPD 
is well known as smoking is the primary risk factor for development of COPD. However, whether 
smoking mentholated versus non-mentholated cigarettes is associated with an increased risk of 
developing COPD is unclear.  For this project, I analyzed data on pulmonary function (as measured 
by forced expiratory volume, percent predicted FEV1, ppFEV1) on 2858 European Americans 
(EA) and 2790 African Americans (AA), a total of 5648 participants who had a smoking history 
greater than 10 pack years, from the COPDGene® multicenter observational study.  Men 
comprised 55.1% of the population and 44.9% were women. EA participants were significantly 
older than AA participants (57.8 versus 53.5 years, respectively, p<0.00001), had smoked 
substantially more pack-years (47.6 versus 38.1 pack-years, respectively, p<0.00001), and had 
lower ppFEV1 (76.4% predicted versus 84.9% predicted, respectively, p< 0.0001).   Overall, 
significantly more European Americans smoked non-menthol cigarettes than menthol cigarettes, 
55.8% versus 44.3%, respectively (p-value < 0.00001), whereas significantly more African 
Americans smoked menthol cigarettes than non-menthol cigarettes, 88.2% versus 11.8%, 
respectively p-value ˂ 0.00001).  An analysis of the effects of age, pack-years, race, and menthol 




increasing age and pack-years, and also was significantly higher in AA versus EA participants 
(p<0.000001 for all).  Menthol versus non-menthol cigarettes smoking was not associated with 
ppFEV1, when race was included, although interactions among the variables was not explored.  
These results confirm previous relationships regarding the effects of age, race, and pack-years on 
ppFEV1, but identified no independent effects of menthol versus non-menthol cigarette smoking.  
However, the relationship between ppFEV1 and age, pack-years, menthol cigarette smoking, race, 
and sex was not straightforward and additional analyses need to be done.  My results indicate that 
the relationships between ppFEV1, age, pack-years and menthol cigarette smoking differ by sex 
and between races, thus, different public health interventions to facilitate smoking cessation and 
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1.1 Definition and Public Health Relevance 
Chronic obstructive pulmonary disease, otherwise known as COPD, is a serious pulmonary 
disease that severely limits pulmonary airflow and presents as a chronic cough, wheezing, 
shortness of breath, and sputum production.  The severe airflow limitation results from a 
combination of two lung conditions, emphysema and chronic bronchitis.  The chronic cough is 
due to chronic bronchitis that results from inflammation.  The shortness of breath is due to 
emphysema that results from damage to the alveoli.  
COPD is a major public health concern, it is the fourth leading cause of death in the United 
States, after heart disease, cancer and accidents (Xu 2018).  In 2018 16.4 million people reported 
a COPD diagnosis of whom,156,979 Americans die each year (National Vital Statistics System – 
Mortality Data (2019) via CDC WONDER). Overall, in 2014, the mortality rate for COPD was 
higher in men than women, 44.3 per 100,000 versus 35.6 per 100,000 (National Vital Statistics 
System – Mortality Data (2019) via CDC WONDER).   
Prevalence and mortality of COPD also differs between European Americans and African 
Americans.  Gillum and colleagues (1990) analyzed data on 76,559 individuals from the National 
Center for Health Statistics. They reported that in 1986, the prevalence of COPD was lower among 
African Americans than among European Americans (African American to European ratio 0.80).  
Furthermore, European American men had the highest mortality rates (approximately 30 deaths 
per 100,000), followed by African American men (approximately 20 deaths per 100,000), 
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European American women (approximately 15 deaths per 100,000), and finally African American 
women (approximately 8 deaths per 100,000).  
The costs of COPD for individuals and society are substantial.  Life expectancy for 
individuals who have COPD and currently smoke with COPD is shorter than that for individuals 
who have COPD and are former smokers or never smokers.  Specifically, Shavelle and colleagues 
reported that the life expectancy of current smokers with more severe disease is 5.8 years less, 
former smokers with more severe disease is 5.6 years less, and individuals who have never smoked 
with more severe disease lose 1.3 years.  In addition to the reduction in lifespan, in 2003 COPD 
incurred a $32.1 billion loss in the United States alone du e to medical costs.  These costs have 
been paid mostly by Medicare, Medicaid and private insurance. (Petty 2006) In 2013, Torabipour 
et al conducted a cost analysis of hospitalized patients with COPD.  This analysis consisted of 165 
subjects that have been diagnosed with COPD, at Imam Khomeini hospital in Iran.  Data was 
obtained retrospectively from billing data.  They reported that the mean costs per patient increased 
from $423.3 in 2011 to $2,436.20 in 2013.   Ford et al performed an analysis using data from 2006-
2010 Medical Expenditure Panel Survey, the 2004 National Nursing Home Survey, and the 2010 
Centers for Medicare and Medicaid Services to find that the mean medical costs including 
hospitalizations and medications per patient was 5.7 times higher in 2013 than 2011.   
Although the prevalence of COPD and its associated costs are high, the burden of disease 
varies by geographic regions.   Using data from the Burden of Obstructive Lung Disease (BOLD) 
study, a study that collected data from multiple countries to identify risk factors and to quantify 
prevalence of obstructive lung disease, Buist et al. estimated global prevalence of COPD to be 
10.1% in 2007 and ranged from 6% in Germany to 19% in Cape Town, South Africa.  The overall 
estimated prevalence of COPD in United States is 10.1%, (Buist 2007), but it varies substantially.  
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As can be seen in figure 1 (derived from BFRSS 2019 data), the prevalence of COPD is highest 
along the Mississippi and Ohio rivers.  
 
Figure 1. COPD Prevalance in the United States  
 
As a result of the high prevalence of COPD overall and its impact on the health individuals 
and society, as well as differences in COPD prevalence by geographic regions and among 
ethnic/racial groups, researchers have been studying the environmental and genetic factors that 
affect the development of COPD since 1959(Ciba 1959).   
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1.2 Forced Expiratory Volume (FEV) as a Measure of Pulmonary Airflow 
As described above, COPD can severely limit pulmonary airflow.  Forced Expiratory 
Volume (FEV), as assessed by spirometry, is a common measure of pulmonary airflow and is used 
in the diagnosis of COPD (Pierce 2005).  Specifically, FEV1 is the volume of air that an individual 
can forcibly expire from their lungs within 1 second after inhaling deeply.  The higher the volume 
of air that individuals can force from their lungs, the better the lung function (Spirometry Testing 
Dec 2013).  Instead of FEV1, clinicians and researchers who study COPD often analyze “percent 
predicted FEV1” which is the ratio of the individual’s measured FEV1 to the mean FEV1 predicted 
for an individual’s age, weight, and sex.  This ratio is expressed as a percent.   
Because of the ubiquity of the use of FEV1 for precent predicted FEV1, I will also refer to 
“precent predicted FEV1” as FEV1 throughout this essay.   
Among individuals without COPD, FEV1 ranges 80% or higher, and most individuals with 
normal pulmonary function have percent predicted FEV1 between 80 – 120%. (Spirometry Testing 
Dec 2013).    
Pulmonary airflow as measured by FEV1 is one of the components of the GOLD stages I-
IV that are used clinically to categorize severity of COPD (GOLD 2021 Report).  COPD patients 
with very mild disease (Stage 1) have FEV1≥80%.  Patients with Stage 2 moderate disease have 
ppFEV1 measures between 50% and 80%.  Stage 3 patients have severe disease with a FEV1 




1.3 Environmental Risk Factors 
Numerous environmental elements have been reported as risk factors for the development 
of COPD, including smoking, second hand smoke, dust, fumes and chemicals, air pollution both 
indoor and outdoor, and childhood respiratory infections such as childhood pneumonia (Hayden 
2015).  As an example of indoor air pollution, in countries in which the mean income of the 
population is low, individuals may be exposed to fumes from cooking indoors with traditional 
open-fire cookstoves.  The fuel used to heat the stoves is usually animal dung and crop scraps 
(Gorlick 2012).  These stoves do not have chimneys resulting in poor ventilation within the home 
and the family members breathing in the polluted air. (Gorlick 2012) Paulin and colleagues (2019) 
assessed the relationship between outdoor air pollution, such as increased ozone levels and FEV1 
values.  They analyzed data from the SPIROMICS Air Pollution Study from November 2011 to 
July 2018.  This study was a multicenter cross-sectional study of 1874 current or former smokers 
from seven urban centers across the United States.  These investigators reported that long term 
ozone exposure was associated with reduced FEV1 (Paulin et al, 2017).  
Hayden and colleagues analyzed data from the COPDGene® cohort (described in Section 
2.1 below) to evaluate a relationship between childhood pneumonia and COPD.  In this cohort, 
854 individuals (8.4% of the population) reported having childhood pneumonia.  Individuals with 
childhood asthma were at increased risk of developing COPD (odds-ratio = 1.4), and FEV1 among 
these individuals was 69.1% when a value of 77.1% was expected (Hayden 2015). 
 
6 
1.4 Tobacco Use 
Tobacco use is the primary risk factor for development of COPD (Hylkema 2007) 
Although numerous tobacco products exist, including pipes, cigars and smokeless tobacco, 
cigarettes are the most frequently used.  Cigarettes were introduced in the United States in the 
early 19th century and were initially rolled by hand. After the invention of the cigarette rolling 
machine, cigarettes became easily accessible to the overall population and lead to more individuals 
smoking (Cross 2014).   
Based on analyses conducted by The American Lung Society (ALS 2020) of data from the 
2015 National Health Interview Survey conducted by the Centers for Disease Control and 
Prevention, smoking rates differ among racial and ethnic populations.  Overall, 16.6% of African 
Americans smoke, which is similar to that or non-Hispanic white (16.6%), and higher than that for 
Hispanics (10.1%) and Asian Americans (7%.).  Indigenous Americans (including Alaskan 
Natives,) have the highest rates (21.9%).  Overall, women smoke less than men but the proportions 
differ by sex.  For example, 20% of African American men versus 13.5% or women smoke, 
whereas the proportions of men and women smokers are more similar among non-Hispanic whites, 
17.3% of men and 16.0% of women.  Substantially fewer women than men smoke among 
Hispanics (7.1 versus 13.1%, respectively) and among Asian Americans (2.6% versus 12.0%, 
respectively).  In contrast, more American Indians/Alaskan Native Indian women smoke (24%, 
compared to men (19%).   
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1.4.1  Menthol cigarettes   
Menthol cigarettes were introduced by Lloyd Hughes (Reid 1993).  Hughes had asthma 
and carried a small container of menthol crystals from which he would breathe vapors for asthma 
relief.  He discovered that cigarettes stored in the same container with the menthol crystals 
absorbed the menthol flavoring and had a cool taste (Reid 1993).  The menthol flavored cigarettes 
were not as harsh as non-menthol cigarettes and thus were more palatable, and marketable, to a 
larger swath of the population including women, youth, and African Americans (Sutton 2004).   
Currently, all cigarettes contain approximately 600 chemicals, inclusive of added menthol 
(either natural or synthetic), even cigarettes marketed as non-menthol cigarettes (Tobacco Products 
Scientific Advisory Committee 2011).  The difference between menthol and non-menthol 
cigarettes is that more menthol, 2.9 to 19.6 mg/cigarette, is added to cigarettes classified as menthol 
in the United States.  Cigarettes classified as non-menthol contain 0.002 to 0.07mg/cigarette of 
menthol (Ai J 2018).   
Menthol versus non-menthol cigarette smoking differs among racial and ethnic 
populations.  Villanti and colleagues (2016) analyzed tobacco use data from the 2004-2014 
National Surveys on Drug Use and Health, a nationally representative survey of the US civilians 
who are greater than 12yo and non-institutionalized.  Across this time-period, they reported that 
the percentages of individuals who smoked menthol cigarettes ranged from a low of 25-29% 
among European Americans, to 30-38% among non-Hispanic Asian Americans, to 37-47% of 
Hispanic Americans, and a high of 84.6-86% of non-Hispanic African Americans. 
Because menthol masks the harshness of cigarettes, researchers have hypothesized that 
high levels of menthol in cigarettes may reduce an individual’s ability to quit smoking.  Recently, 
results from a few studies support this hypothesis.   In 2014, Smith and colleagues reported results 
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of their clinical trial of 1504 adult smokers with a smoking history of at least 10 cigarettes per day 
within the past 6 months (Smith 2014) who had also expressed an interest in quitting smoking.  
The study group was comprised of 814 white non-menthol and 439 menthol cigarette smokers, as 
well as 186 African American menthol smokers.  The number of African American non-menthol 
smokers (n= 16) was too low to provide meaningful results and were excluded from the analyses.  
Smoking status was collected at 4, 8 and 26 weeks after the adults ceased smoking.  The 
researchers reported that menthol cigarette smokers were less likely to have smoking cessation 
success (OR=0.72; C.I = 0.60 to 0.87). Menthol cigarette smokers also had a higher nicotine 
dependence, fewer prior attempts to quit, and less confidence in being able to quit smoking.  The 
researcher’s model also predicted that the probability of continued smoking abstinence for non-
menthol versus menthol cigarette smokers was 45% vs. 37%, respectively (Smith 2014).   
In addition to the results on smoking cessation among menthol versus non-menthol 
cigarette smokers, Smith and colleagues reported that African American women had a higher risk 
of failure compared to white women OR=2.63 (C.I = 1.75, 3.96) However, no differences were 
observed between smoking cessation frequency in white versus African American men OR=1.01 
(C.I. = 0.59, 1.74) (Smith 2014).   
1.5  Rationale for Current Study and Gaps in Knowledge 
Because the primary risk factor for COPD is smoking, knowledge of variables that increase 
smoking would enable the development of targeted interventions to reduce smoking and thus may 
prevent many cases of COPD.   The addition of menthol to cigarettes masks the harshness of 
cigarette smoke.  Furthermore, a few studies have indicated that individuals who smoke menthol 
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cigarettes are less likely to be able to quit smoking.  The effect of smoking menthol versus non-
menthol cigarettes on FEV1 and the possible development of COPD is unclear.  In the current 
study, I assessed the effects of several risk factors, including age, pack-years, race, and menthol 
versus non-menthol cigarettes, on FEV1 and categories of FEV1 that correspond to the GOLD 
stages for COPD. 
 
1.6 Hypothesis and Specific Aims  
The overall goals of the current study are to assess (1) whether smoking menthol versus 
non-menthol cigarettes is an independent risk factor for decreased FEV1, and (2) whether the 
effects of this possible risk factor differ between European Americans and African Americans. 
To achieve this goal, I performed the following specific aims using data from the 
COPDGene® study: 
 
(1) Assess whether measures of FEV1 and a variety of risk factors (including age, pack-
years, sex, smoking behaviors) differed between European Americans and African Americans. 
 
(2)  Assess whether measures of FEV1 and a variety of risk factors (including age, pack-
years, sex, smoking behaviors) differed between menthol versus non-menthol cigarette smokers 




(3) Assess whether age, pack-years, race, and menthol versus non-menthol cigarette 





2.1 COPDGene® Study  
COPDGene® is an observational study with a primary objective to identify genetic factors 
that contribute to COPD (Regan et al 2010).  This multicenter study has enrolled over 10,000 
patients from 21 sites in the Unites States. Non-Hispanic European American men and women, 
and African American men and women between the ages of 45 and 80 were recruited through 
radio ads, health fairs, and identified from registry databases in research offices for participation 
in this study.  The four subject groups in this study are: (1) COPD participants who have a 
diagnosis of COPD Gold Stage 1-4, (2) participants with FEV1 less than 80% who do not have a 
Gold Stage diagnosis (e.g., Gold Stage Unclassified), (3) smokers without COPD (and no Gold 
Stage diagnosis) with FEV1 greater than 80%, and (4) non-smoking controls.   As described in 
section 1.2, the 4 Gold Stages are used to indicate the severity of diagnosed COPD (GOLD 2021 
Report).  All groups, except the non-smoking controls had a smoking history greater than 10 pack 
years (1 pack of cigarettes per day for 10 years). To be included in COPDGene® the non-smoking 
controls had to have smoked less than 101 cigarettes over their lifetime.  Exclusion criteria for the 
COPDGene® study included:  a lung disease other than COPD, chronic bronchitis, or emphysema. 
Participants were also excluded if they had previous lung surgery to remove one lobe or more of 
the lung. All participants were able to complete spirometry and all participants self-assigned to 




Participants of the COPDGene® trial consented to multiple procedures and data collection 
activities.  Data on pack years (packs per day/years smoked), and whether the participant currently 
smokes or previously smoked menthol cigarettes was self-reported by the participant completing 
questionnaires and medical history forms. All participants completed (1) pre- and post-
bronchodilator spirometry tests to measure airflow obstruction, (2) blood collection to test for the 
alpha 1 antitrypsin deficiency and other proteins associated with COPD, (3) a 6-minute walk test 
to measure exercise capacity, and (4) a chest CT scan to measure emphysema and any airway 
disease.   
2.2.1   Measurement of Airflow 
For each participant, pulmonary airflow was measured by spirometry, specifically using 
Forced Expiratory Volume (FEV). FEV1 is the measurement of how much air you can forcibly 
move from your lungs in 1 second.  The higher volume of air that can be forced from the lungs the 
better the lung function. Variability of spirometry results are minimized by performing the 
spirometry procedure once without a bronchodilator, administering a bronchodilator and, waiting 
until optimal absorption level is achieved and then administering the spirometry procedure again. 
For the current study, I used percent predicted FEV1 percent, that is, the ratio of the measured 
FEV1 to the FEV1 predicted based on the individuals age, sex, and weight cohort (see section 1.2).   
In addition to analyzing FEV1 as a quantitative trait, I also divided the participants into categories 
of pulmonary airflow based on their FEV1 results:  high (FEV1≥80%, medium (FEV1 between 
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50% and 80%, low (FEV1 between 30% and 50%) and very low FEV1˂30%.  These categories 
correspond to Gold Stages I-IV described in section 1.2.  
For this project I only included participants who answered the question on the medical 
history questionnaire “Do you now smoke or did you smoke menthol cigarettes?” 
2.3 Statistical Methods 
I first tested for differences for a variety of traits between European Americans and African 
Americans.  Differences between the two groups were assessed using chi-squared tests for 
categorical data (such as sex) (Using the chi-square calculator from Social Science Statistics) and 
t-tests for quantitative measures (using the data analytics toolpak add-in from excel), such as 
FEV1.  Because I was interested in the possible relationships between these traits and participants 
who smoked menthol versus non-menthol cigarettes, I next performed analyses between menthol 
and non-menthol cigarette smokers within European American and African American groups 
separately. Finally, I used general regression analysis (Using excel data analytics toolpak add-in 
from excel) to assess the effects of age, pack-years, race, and menthol versus non-menthol cigarette 




3.0  Results 
3.1 Characteristic of the Study Population 
Data on a total of 5648 participants was available for the current study of possible 
relationships between menthol versus non-menthol cigarette smokers on FEV1 and COPD-related 
risk factors (such as age, sex, and pack-years).  The total number of European American 
participants was similar to the number of African American participants, n=2858 versus 2790, 
respectively (Table 1).  More males than females were recruited, 55.1% versus 44.9%, overall, and 
the proportion of African American male participants was higher than the proportion of European 
American participants, 56.3% versus 53.8%, respectively, although these differences were not 
statistically significant (p=0.056).  Participants ranged in age from 39 to 85 years old and mean 
age of the total population was 55.7 years.  European Americans were 4.3 years older than African 
Americans (57.8 versus 53.5 years, respectively) and this difference was significant (p-value = 




Table 1. Population Characteristics  
 Total European 
American 
African American Test statistic ( 
2 or t-test) and 
p-value 
n 5648 2858 2790  
     
Sex    21 = 3.65, 
p=0.055974  
      Male (%) 3110 (55.1%) 1538 (53.8%) 1572 (56.3%)  
      Female (%) 2538 (44.9%) 1320 (46.2%) 1218 (43.7%)  
     
Age at visit, years 
(Mean ± sd, range) 
 
55.67 ± 7.52; 
range: 39 - 85 
 
 
57.84 ± 7.98 53.46 ± 6.28 t=22.89,  
p-value = 
6.36x10-111 
     
Smoking      
Current Vs Former    X21 = 34.443,  
p-value 
˂0.00001  
             Current (%) 5333 (94.4%) 2648 (92.7%) 2685 (96.2%)  
             Former (%) 315 (5.6%) 210 (7.3%) 105 (3.8%)  
     
Pack years.  
(Mean ± sd; range) 
42.91 ± 23.29; 
range 10 - 
237.2 
47.62 ± 24.10 38.08 ± 21.38 t= 15.74,  
p-value = 
1.24x10-54 
     
Cigarette type     21= 1217,  
p-value 
˂0.00001  
     Menthol.     (%) 3722 (65.9%) 1262 (44.2%) 2460 (88.2%)  
     Non-menthol.    (%) 1926 (34.1%) 1596 (55.8%) 330 (11.8%)  
     
FEV1     
FEV1 ratio, %) 
(Mean ± SD; range) 
80.61 ± 22.46; 
range: 10.3 - 
159.9 






Table 1 (continued)  
FEV1 Category     25= 148.69,  
p-value 
˂0.00001  
FEV1˃80.1% 3166 (56.1%) 1405 (49.2%) 1761 (63.1%)  
FEV1 50.1%-80% 1863 (33%) 1026 (35.9%) 837 (30%)  
FEV1 30.1%-50% 459 (8.1%) 311 (10.9%) 148 (5.3%)  
FEV1 ˂30% 160 (2.8%) 116 (4%) 44 (1.6%)  
 
With respect to smoking behaviors, most of the participants were current smokers, only 
5.6% self-reported as former smokers.  Although the proportions were low, more European 
Americans were former smokers than were African Americans (7.3% versus 3.8%, respectively; 
p-value < 0.00001).  The number of pack-years of cigarettes smoked ranged widely, from a low of 
10 pack-years to a maximum of 237.2 pack-years.  European American participants smoked an 
average of 9.5 pack years more than African American participants (47.6 versus 38.1 pack-years, 
respectively), this difference was highly significant (p = 1.24x10-54 (Table 1).  The proportions of 
non-menthol versus menthol cigarette smokers varied substantially between European and African 
American participants.  European Americans smoked more non-menthol cigarettes versus menthol 
cigarettes (55.8% versus 44.3%, respectively), whereas African Americans smoked more menthol 
cigarettes than non-menthol cigarettes (88.2% versus 11.8%, respectively), and these differences 
were highly significant (p-value < 0.00001). 
Overall, mean pulmonary function, as measured by FEV1, ranged from a low of 10.3% to 
a high of 159.9%.  FEV1 was significantly higher among African Americans than among European 
Americans, mean FEV1was 84.9% versus 76.4%, respectively; p-value = 9.67 x 10-42.  As can be 
seen in Table 1, this overall difference in FEV1 is also reflected in the proportion of participants 
within each of the FEV1 categories.  A higher proportion of African Americans (63.1%) had 
pulmonary function greater than 80.1%, whereas slightly less than one-half (49.2%) of European 
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Americans were in the high function category.  Similarly, approximately half as many African 
Americans as European Americans had poor (FEV1 from 30.1-50%) or severely poor (FEV1 < 
30%) pulmonary function.  For example, 1.6% of African Americans were in the severely poor 
category versus 4% of European Americans.  These differences in frequencies among the FEV1 





















(X2 or t-test) 
and p-value 
 Menthol Non-Menthol  Menthol Non-Menthol  
 1262 1596  2460 330  
Sex   X2=1.8767, 
p-value is 
.1707 
  X2=3.61, p-
value = 
0.0576 






















       
Age at visit 
(Mean ± sd) 
56.9±7.78 58.58±8.06 t=-5.62,  
p-value = 
2.09x10-8 
53.11±5.99 56.04±7.59 t=-8.06, p-
value = 
1.11x10-15 
       
Smoking    x2=5.16,  
p-value = 
.023 
























       
Pack years.  
(Mean ± sd) 
47.08±23.62 48.05±24.48 t=-1.07,  
p-value = 
0.29 
37.96±20.94 39.95±24.42 t=-0.79, p-
value = 0.43 
       
FEV1 
(Mean ± sd) 
77.30±22.30 75.7±22.93 t=1.88,  
p-value = 
0.059 
85.08±20.96 83.63±24.46 t=1.16,  
p-value = 
0.25 
       
FEV1 Range   x2=16.11,  
p-value = 
0.0011 
  x2=14.94,  
p-value = 
0.0018 
FEV1˃80.1% 655(51.9%) 750(47%)  1551(63%) 210(63.6%)  
FEV1 50.1%-
80% 
424(33.6%) 602(37.7%)  754(30.7%) 83(25.2%)  
FEV1 30.1%-
50% 
147(11.6%) 164(10.3%)  122(5%) 26(7.9%)  
FEV1 ˂30% 36(2.9%) 80(5%)  33(1.3%) 11(3.3%)  
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I next assessed the relationships between participants who smoked menthol versus non-
menthol cigarettes within the European American and African Americans populations separately 
(Table 2). As noted in Table 1, more European American participants smoked non-menthol 
cigarettes, whereas more African Americans smoked menthol cigarettes. The proportions of 
European American men (and women) who smoked menthol versus non-menthol cigarettes were 
similar.  For example, men comprised 52.4% of menthol cigarette smokers and 55% of non-
menthol cigarette smokers and this difference was not significant (p-value = 0.17).  Among African 
American participants, men comprised 56% of the menthol cigarette smokers and 61.2% of the 
non-menthol cigarette smokers, but this difference was not significant (p < 0.058),   
Menthol cigarette smokers were significantly younger than non-menthol cigarette smokers 
for both European American and African American participants.  European American menthol 
cigarette smokers were 1.7 years younger on average than non-menthol cigarette smokers (age = 
56.9 versus 58.6 years, respectively; p-value = 2.09 x 10-8).  African American menthol cigarette 
smokers were 2.9 years younger than non-menthol cigarette smokers (age = 53.1 versus 56.0 years, 
respectively; p-value = 1.11 x 10-15).   Overall, the numbers of former smokers comprised only 
5.6% of the total population (Table 1).  However, the proportion of non-menthol cigarette smokers 
who were former smokers was significantly higher than the proportion of menthol cigarette 
smokers who were former smokers among both European and African American participants (p-
values = 0.023 and < 0.0001, respectively) (Table 2).    
For both European Americans and African Americans, the number of pack-years were 1-2 
years lower, respectively, among menthol versus non-menthol cigarette smokers, but these 
differences were not significant (Table 2).  Similarly, although FEV1 was 1.4 - 1.6% higher for 
menthol versus non-menthol cigarette smokers among both European and African American 
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participants, these differences were not significant (see Table 2 and Figure 2).  In contrast, the 
relative proportions of participants in the 4 different FEV1 categories differed significantly 
between menthol versus non-menthol smokers among both European and African American 
participants (p-values < 0.001 for both).  In general, menthol cigarette smokers had better 
pulmonary function than non-menthol cigarette smokers.  Among European Americans, a lower 
proportion of non-menthol smokers than menthol smokers had FEV1<30% (2.9% versus 5%, 
respectively).  Also, a higher proportion of menthol smokers versus non-menthol smokers had 
mild or no disease, FEV1>80.1%) (51.9 versus 47%, respectively), Among African Americans, a 
similar proportion of menthol versus non-menthol cigarette smokers had FEV1 > 80.1% (63% 
versus 63.6%, respectively).  However, lower proportions of menthol cigarette smokers compared 
to non-menthol cigarette smokers had poor FEV1 outcomes; 6.3% of menthol cigarette smokers 
versus 11.2% of non-menthol cigarette smokers had FEV1 <50%.   
 
 

















Menthol vs Non-menthol FEV1
Menthol Frequency Non-menthol Frequency
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Finally, I performed a general linear model (GLM) analysis and assessed the simultaneous 
effects of age, pack-years, race, and menthol/non-menthol cigarette use on FEV1; the results are 
presented in Table 3.  Overall, these variables accounted for 9.9% of the total variation FEV1 (r2 
= 0.0987, p-value = 1.4x10-125).  As can be seen in Table 3 (and Appendix A; Figures 1- 4), FEV1 
significantly decreased with both increasing age ( = -0.51; p-value = 4.2x10-34) and increasing 
number of pack years ( = -0.145; p-value = 2.3x10-28).  Furthermore, FEV1 was significantly 
higher among African American participants than among European American participants ( = 
4.72; p-value = 9.3x10-13).   Menthol versus non-menthol cigarette use was not significantly 
associated with FEV1 after inclusion of age, pack-years, and race. 
 
Table 3. Estimate of Effects of Age, Pack Years, Race and Menthol Cigarettes on FEVI  
 Coefficients ± Standard Error t Stat P-Value 
Age at Visit -0.510± 0.042 -12.2 4.21x10-34 
Pack-years -0.145± 0.013 -11.1 2.30x10-28 
Race (EA = 0, AA=1) 4.72 ± 0.66 7.15 9.38x10-13 
Menthol/Non-menthol 0.38 ± 0.68 0.55 0.58 
    




4.0  Discussion 
Based on an analysis of the Center for Disease Control and Prevention’s National Health 
Interview Survey data from 1965-2018, the American Lung Associations states that the prevalence of 
current cigarette smoking among U.S. adults declined from 42.4% in 1965 to 13.9% in 2017 (ALA 
Overall Tobacco Trends) Between 1997 and 2015, the overall prevalence of smoking in the US 
decreased almost 10% between 1997 and 2015; prevalence was 25.7% in 1997 and 15.1% in 2015. 
(Ward et al., 2016) This overall reduction in smoking was primarily due to a decrease in the proportion 
of non-menthol cigarette smokers versus menthol cigarette smokers. For example, among individuals 
aged 26+ years, the prevalence of non-menthol cigarette smokers was 17.4% in 2004 and 13.4% in 
2014 (Villanti et al., 2016).  In contrast, among menthol cigarette smokers of the same age and time 
frame, the prevalence increased between from 7.1 to 7.8% respectively (Villanti et al., 2016).   
Furthermore, as described in the Introduction, and also in a review by Villanti and colleagues (2017), 
menthol cigarette smokers are less successful at quitting cigarettes than non-menthol cigarette smokers 
across multiple ethnic and racial groups, despite their increased number of quit attempts.   Thus, 
menthol cigarette smokers may be at increased risk of developing COPD. 
As described in the Introduction, cigarette smoking, increased age, and number of pack-years 
are strongly associated with increased risk of COPD.  Given the higher prevalence of menthol cigarette 
smokers in African Americans and reports that menthol cigarette smokers are less successful at long-
term smoking cessation, African Americans may have poorer measures of FEV1 and thus have an 
increased risk of developing COPD.  In this project, I assessed the relationship between FEV1 (a 
surrogate for COPD risk) and risk factors for poor pulmonary function using data on 5648 participants 
who were current or former smokers from the COPDGene® study.  
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By design, the number of European American (n=2858) and African American (n=2790) 
recruited into the COPDGene® study were similar.  Consistent with the observation that males have 
a higher prevalence of COPD, more males (55.1%) than females (44.9%) were present in the study, 
although the relative proportions of males versus females did not differ significantly between European 
Americans and African Americans (Table 1).  Consistent with previous reports (Villanti et al., 2016), 
women were more likely to smoke menthol cigarettes versus non-menthol cigarettes than were men. 
In European Americans 45.5% of women versus 42.9% of men smoked menthol cigarettes, whereas 
in African Americans 89.5% of women and 87.1% of men smoked menthol cigarettes, although these 
differences were not statistically significant (Table 2).  Although women currently have a lower 
prevalence of COPD than men, given that individuals who smoke menthol cigarettes have more 
difficulty quitting smoking, COPD prevalence may increase among women smokers in the future. 
African American participants were significantly more likely to smoke menthol cigarettes than 
European Americans (88.2% versus 44.2%, respectively).  Although these proportions are higher than 
those reported by the CDC, 76.8% in non-Hispanic blacks and 24.6% of white adults, the relative 
proportions are similar.(CDC, 2020 Menthol and Cigarettes)  Overall, African American participants 
were 4.3 years younger than European American participants and menthol cigarette smokers were 
significantly younger than non-menthol cigarette smokers among both European American and 
African American participants, 1.7 and 2.9 years, respectively (Table 2).  These results are also 
consistent with previous reports that menthol cigarette smokers were younger than non-menthol 
cigarette smokers (Rath et. al., 2016) and that the proportion of adolescents who smoked menthol 
cigarettes were more likely to progress to becoming a long-term smoker (reviewed by Villanti et al., 
2017). 
In the current study, African Americans smoked significantly fewer pack years than 
European Americans (38.1 versus 47.6 pack-years).   Furthermore, the number of pack-years was 
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1-2 years lower among menthol versus non-menthol cigarette smokers in European and African 
Americans, although this difference was not significant.  These results are similar to other reports 
that African Americans smoke fewer cigarettes than European Americans, (CDC, 2020, African 
Americans and Tobacco Use).  Differences in the ages and pack years between the two groups 
may be due to the difference in price of menthol versus non-menthol cigarettes.  Because the 
proportion of African Americans smoking menthol cigarettes is higher than that of European 
Americans, and menthol cigarettes are more expensive, African Americans may smoke fewer 
cigarettes (Mills et al 2015).  Mills et. al. also reported that a few menthol brands offer promotional 
prices in predominately black neighborhoods, thus resulting in more African Americans smoking 
menthol cigarettes.  In addition, the additives in menthol cigarettes might reduce the number of 
cigarettes  needed to obtain the same effects. Tauros et al also reported that African Americans are 
more likely to smoke menthol cigarettes and fewer cigarettes, than are European Americans.  
Tauros also reports that menthol and non-menthol cigarettes are not considered substitutes for each 
other. Thus, even if the price of menthol cigarettes went up, the smoker would not be inclined to 
start smoking non-menthol nonmenthol cigarettes instead.  Pulmonary function (as measured by 
FEV1) was significantly better among the African American (84.9%) compared to the European 
American participants (76.4%). Although mean FEV1 was ~1.5% higher in menthol cigarette 
smokers than non-menthol cigarette smokers, this difference was not significant.  However, the 
proportion of menthol versus non-menthol smokers who fell into each FEV1 category was 
significantly different among both European and African Americans.  These results are consistent 
with the observations that African American participants and menthol cigarette smokers were 
younger and smoked fewer pack-years.   
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Finally, I assessed whether age, pack-years, race, and menthol cigarette smoking were 
independently associated with FEV1.  As expected from the univariate results and the literature 
reports, age, pack-years, and race were significantly, and independently associated with FEV1, 
Appendix Table A2.  In contrast, menthol cigarette smoking was not a significant independent risk 
factor for FEV1, although it was positively associated with increased FEV1 (Table 3).   
4.1  Limitations of the Current Study 
In comparison with reports in the literature, the current study is relatively small, that is 
~5,600 individuals versus >57,000 individuals from the large CDC data sets.  Although menthol 
cigarette smoking was not an independent risk factor for FEV1, it may interact with other risk 
factors.  For example, when race was not included in the regression model, menthol (versus non-
menthol) cigarette smoking was significantly associated with increased FEV1 ( = 2.44, p-value 
= 7.9x10-5; Appendix Table A1.   
 Furthermore, although the age difference between European and African American 
participants was 4.4 years, the number of pack years differed by 9.6 years, indicating a possible 
interaction among the age, pack-years, race, and menthol smoking variables.  Finally, the possible 
effects of sex could be included in a multivariable regression analysis.  These analyses were 
beyond the scope of my current project, although they may lead to additional insights. 
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4.2  Conclusions 
Similar to results in the literature, my results indicate that decreased FEV1, as a measure 
of poorer pulmonary function, and a marker for COPD, is significantly associated with increasing 
age, increasing number of pack-years, and European American (versus African American) status.   
Menthol versus non-menthol cigarette smoking did not have any significant effects on FEV1 
percent.  However, the relationships between FEV1, age, sex, pack-years, race, and menthol versus 
non-menthol cigarette smoking were not straightforward, indicating the presence of possible 
interactions among these variables.  Future directions may include studies of possible interactions 
between race, menthol, pack years, FEV1 and age.  In addition, studies of the effect of menthol 






Figure A 1. European Americans FEVI vs Age 
 
 




Figure A 3. European Americans FEVI vs Pack Years 
 
 





Table A 1. Estimate of Effects of Age, Pack Years, and Menthol Cigarettes on FEVI 
 Coefficients ± Standard Error t Stat P-Value 
Age at Visit -0.56± 0.04 -13.56 3.00x10-41 
Pack-years -0.16± 0.01 -11.96 1.50x10-32 
Menthol/Non-menthol 2.44 ± 0.62 3.95 7.96x10-5 
    
r2 0.09  8.27x10-116 
 
Table A 2. Estimate of Effects of Age, Race, and Pack Years on FEVI 
 Coefficients ± Standard Error t Stat P-Value 
Age at Visit -0.51± 0.04 -12.40 7.32x10-35 
Race 4.88± 0.60 8.16 3.99x10-16 
Pack Years -0.14 ± 0.01 -11.10 2.50x10-28 
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